Primary progressive aphasia

SciSparc to Conduct a Phase IIa Clinical Trial in Alzheimer's Patients Using the Company's Proprietary Cannabinoid-Based Treatment

Retrieved on: 
Wednesday, February 17, 2021
Cognitive disorders, Psychiatric diagnosis, Learning disabilities, Psychiatry, Branches of biology, Abnormal psychology, Aphasias, Dementia, Alzheimer's disease, Vascular dementia, Primary progressive aphasia

Alzheimer's disease is the most common type of dementia, accounting for over two-thirds of cases of dementia.

Key Points: 
  • Alzheimer's disease is the most common type of dementia, accounting for over two-thirds of cases of dementia.
  • Alzheimer's disease is a neurodegenerative disease that causes progressive and disabling impairment of cognitive functions including memory, comprehension, language, attention, reasoning and judgment.
  • The current pharmacological treatment of agitation in Alzheimer's disease has an unsatisfactory benefit/risk ratio and often involves using off-label drugs.
  • The Alzheimer's center treats hundreds of patients a year, as inpatients, outpatients and as part of its diagnosis and counseling services.

Primary Progressive Aphasia | 2020 Clinical Development Scenario and Growth Prospects - ResearchAndMarkets.com

Retrieved on: 
Monday, April 20, 2020
Pharmaceutical, Health, Clinical trials, Aphasias, Dementia, Medicine, Human communication, Neurological disorders, Communication disorders, Language disorders, Stroke, Primary progressive aphasia, Expressive aphasia

Primary Progressive Aphasia Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Primary Progressive Aphasia market.

Key Points: 
  • Primary Progressive Aphasia Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Primary Progressive Aphasia market.
  • A detailed picture of the Primary Progressive Aphasia pipeline landscape is provided, which includes the disease overview and Primary Progressive Aphasia treatment guidelines.
  • The assessment part of the report embraces in-depth Primary Progressive Aphasia commercial assessment and clinical assessment of the Primary Progressive Aphasia pipeline products from the pre-clinical developmental phase to the marketed phase.
  • How many Primary Progressive Aphasia emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Primary Progressive Aphasia?

CurePSP Supports the FTD Disorders Registry With $100,000 Grant

Retrieved on: 
Tuesday, November 12, 2019
General Health, Fund Raising, Health, Other Philanthropy, Philanthropy, Cognitive disorders, Neurological disorders, Dementia, Brain, Nervous system, Psychiatric diagnosis, Rare diseases, Learning disabilities, Frontotemporal dementia, Primary progressive aphasia, Progressive supranuclear palsy, Corticobasal degeneration, CurePSP, the Rainwater Charitable Foundation

CurePSP, the foundation for prime of life neurodegeneration, has made a $100,000 grant to support the work of the FTD Disorders Registry.

Key Points: 
  • CurePSP, the foundation for prime of life neurodegeneration, has made a $100,000 grant to support the work of the FTD Disorders Registry.
  • The funding from CurePSP adds to more than $500,000 that RCF has granted to support the FTD Disorders Registry.
  • The FTD Disorders Registry enrolls patients and their caregivers, family members, and friends who have been affected by disorders involving frontotemporal degeneration, which include behavioral variant frontotemporal dementia (bvFTD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), primary progressive aphasia (PPA), and FTD with amyotrophic lateral sclerosis (ALS).
  • CurePSP looks forward to further collaboration with the FTD Disorders Registry through funding and marketing.